KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

RIYADH, Saudi Arabia, May 10, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSH&RC) has experienced a year of achievements across its three Centres of Excellence—Oncology, Genomics, and Transplantation.

KFSH&RC’s Oncology Centre of Excellence continues to lead the fight against the disease in the Kingdom. This year alone, the centre has treated 25% of all cancer cases in Saudi Arabia, achieving a 50% overall recovery rate and up to 90% recovery in leukemia cases. With almost five decades of service, the centre’s commitment to providing advanced cancer treatments is evident in its adoption of technologies such as CAR T-cell therapy and liquid biopsy, which provide less invasive alternatives to traditional methods, along with extensive bone marrow transplants, and revolutionary techniques like Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

Notably, KFSH&RC has achieved a milestone by completing over 100 CAR T-cell therapy procedures, a novel treatment that genetically modifies a patient’s immune cells to fight cancer. This achievement puts it on par with renowned institutions that are also advancing CAR-T cell therapy for various blood cancers and exploring expanded applications through clinical trials and new treatment protocols. Furthermore, the centre’s focus on pediatric oncology boasts a 97% five-year survival rate for renal tumors and a 92% survival rate for acute lymphoblastic leukemia in children.

With rapid advancements in genomic medicine, KFSH&RC is adopting next-generation sequencing technologies into patient care in its Genomic Centre, revolutionizing local and regional approaches to disease management. KFSH&RC’s discovery of the bacterial strain Stenotrophomonas Riyadhensis, facilitated by whole-genome sequencing (WGS) technology, has contributed to our understanding of bacterial antibiotic resistance mechanisms. With 15,698 patient visits and over 5,658 whole genomes completed in 2023, the centre ensures that prevention, diagnosis, and treatment are precise and personalized.

KFSH&RC’s Organ Transplant Centre of Excellence (OTCoE) continues to be the primary contributor to organ transplantation activities in the Kingdom, accounting for 65% of all transplants performed nationally. In 2023, OTCoE performed 1,092 solid organ transplants, including the world’s first fully robotic liver transplant— where doctors employed robotic technology to conduct surgery on both patient and donor — an achievement that places the centre at the forefront of global transplantation practices.

As KFSH&RC continues to push the boundaries of what is possible in medical science, its efforts not only inspire but also significantly impact the global healthcare community, reaffirming its role as a leader in medical innovation and specialized healthcare.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2024, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally for the second consecutive year. Additionally, in 2024, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

CONTACT INFORMATION

For more information, please contact:

Mr. Essam Al-Zahrani, Acting Media Affairs Head, 0555254429

Mr. Abdullah Al-Aown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e99afd2f-d5c6-400e-9290-26b36a580bee

GlobeNewswire Distribution ID 9115490

Curia e Carterra Fazem Parceria em Simpósio para o Avanço da Pesquisa Biotecnológica do Noroeste do Pacífico

ALBANY, N.Y. e SALT LAKE CITY, May 10, 2024 (GLOBE NEWSWIRE) — A Curia, uma organização líder em contratos de pesquisa, desenvolvimento e fabricação, e a Carterra Inc., líder mundial em descoberta de medicamentos de moléculas pequenas e anticorpos de alto rendimento sem rótulos, anunciaram hoje sua parceria para a realização de um simpósio de produtos biológicos de alto rendimento previsto para 31 de maio no Residence Inn do Marriott em Seattle, Washington.

O objetivo da colaboração é promover o crescente foco em biotecnologia na região Noroeste do Pacífico dos EUA e Canadá. O simpósio reunirá todos os níveis de liderança científica das comunidades de biotecnologia e farmacêutica.

“Estamos muito entusiasmados com a parceria com a Carterra para organizar este simpósio de descoberta de anticorpos, reunindo a comunidade de biotecnologia do Noroeste do Pacífico e compartilhando os mais recentes avanços na descoberta de anticorpos”, disse Steve Lavezoli, Vice-Presidente de Produtos Biológicos da Curia. “Também estamos prontos para compartilhar nossos fluxos de trabalho de descoberta ideal de anticorpos de alta qualidade e acelerados para a primeira descoberta, desenvolvimento e fabricação clínica de anticorpos humanos. Os anticorpos descobertos e/ou projetados com a tecnologia de plataforma da Curia são para a área de clínica e temos mais de 230 campanhas bem-sucedidas de descoberta de anticorpos realizadas para a comunidade de biotecnologia.”

A velocidade, a experiência científica e a eficiência podem superar as altas taxas de atrito da descoberta precoce de anticorpos e alcançar a primeira distribuição no mercado de novas terapêuticas. O simpósio destacará a plataforma tecnológica e os serviços integrados da Curia com foco no desenvolvimento de sistemas aprimorados de camundongos para geração de anticorpos e triagem de células B únicas de alto rendimento. A combinação de sequenciamento de próxima geração (NGS) e produção recombinante rápida de quantidades de miligrama para grama de anticorpo monoclonal purificado (mAb) acelera significativamente a identificação de condutores candidatos ao desenvolvimento.

Desde 2017, a Carterra tem vendido seu potente biossensor de alto rendimento LSA® para analisar e caracterizar anticorpos com Ressonância Plasmônica de Superfície (SPR). Com o lançamento da sua plataforma LSAXT no ano passado, a Carterra passou a oferecer produtos que podem realizar análises de moléculas pequenas, bem como a descoberta de anticorpos. A plataforma LSA foi destaque em vários artigos revisados por pares em Science, Nature e Cell, detalhando o caminho de várias terapêuticas que estão entrando em ensaios clínicos. No simpósio, vários cientistas líderes em biofarmacêutica compartilharão suas ideias sobre suas áreas específicas de descoberta de medicamentos e destacarão o impacto transformador da integração da tecnologia HT-SPR, IA/ML e outras novas tecnologias.

“Estamos entusiasmados com a nossa parceria com a Curia no nosso simpósio. Os simpósios Carterra são eventos científicos que organizamos todos os anos nos EUA e na Europa”, disse Chris M. Silva, Vice-Presidente de Marketing e Produtos da Carterra. “Esses simpósios nos ajudam a compartilhar os mais recentes avanços tecnológicos e dados importantes gerados a partir dos fluxos de trabalho de cientistas que usam as plataformas sem rótulos da Carterra. A nossa entrada no noroeste do Pacífico é uma oportunidade para aumentar o entendimento mais profundo da tecnologia para produtos farmacêuticos e biotecnológicos nesta região.”

Clique aqui para confirmar presença no evento. É necessário inscrição pois temos vagas limitadas.

Sobre a Curia:
A Curia é uma Organização de Desenvolvimento e Fabricação de Contratos (CDMO) com mais de 30 anos de experiência, uma rede integrada de 27 locais globais e mais de 3.500 funcionários em parceria com clientes biofarmacêuticos para levar ao mercado terapias que mudam a vida. Nossas ofertas de produtos biológicos e pequenas moléculas abrangem a descoberta através da comercialização, com capacidades regulatórias e analíticas integradas. Nossos especialistas científicos e de processos, e instalações de última geração oferecem a melhor experiência em fabricação de medicamentos e produtos farmacêuticos. Da curiosidade à cura, proporcionamos todas as etapas para a melhoria da vida dos pacientes. Visite-nos em curiaglobal.com.

Sobre a Carterra, Inc.:
A Carterra, Inc. é uma empresa privada. Sua tecnologia HT-SPR fornece aos clientes de descoberta de medicamentos de moléculas grandes e pequenas, o rendimento e a funcionalidade de triagem e caracterização que são dimensionados com aplicativos de nível ômico, condensando meses de trabalho em dias. Nossas soluções viabilizaram múltiplas terapias e pesquisas inovadoras e ajudaram pesquisadores acadêmicos e translacionais e empresas biofarmacêuticas em oncologia, imunologia, neurociência e muito mais.  A Carterra está sediada em Salt Lake City, Utah, e tem Centros de Experiência do Cliente em São Francisco, Salt Lake City, Boston, Manchester, Inglaterra e Munique, Alemanha. Os produtos Carterra estão disponíveis na Ásia-Pacífico e na Oceania através do nosso distribuidor exclusivo, Revvity. Para mais informação, visite www.carterra-bio.com ou conecte-se conosco no LinkedIn ou X (Twitter).

Contato da Curia:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Contato para Mídia da Carterra:
Cheri Salazar
(408) 594-9400
csalazar@carterra-bio.com

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/020a0a28-86f0-4f6c-96f2-0eaa01c82784

GlobeNewswire Distribution ID 9115418

Curia et Carterra coorganisent un symposium sur les produits biologiques pour encourager la recherche en biotechnologie dans le nord-ouest du Pacifique

ALBANY, New York et SALT LAKE CITY, 10 mai 2024 (GLOBE NEWSWIRE) — Curia, une organisation de premier plan du domaine de la recherche, du développement et de la fabrication sous contrat, et Carterra Inc., leader mondial de la découverte d’anticorps et de médicaments à petites molécules sans étiquette à haut débit, annoncent ce jour un partenariat ciblé sur l’organisation d’un symposium sur les produits biologiques à haut débit, prévu le 31 mai au Residence Inn at Marriott de Seattle, dans l’État de Washington.

L’objectif de cette collaboration vise la promotion de l’intérêt croissant suscité par la biotechnologie dans la zone nord-ouest du Pacifique des États-Unis et du Canada. Le symposium réunira des professionnels de tous niveaux de direction scientifique de la biotechnologie et de la pharmaceutique.

« Nous sommes ravis de nous associer à Carterra pour organiser ce symposium axé sur la découverte d’anticorps, qui réunira l’ensemble de la communauté biotechnologique du nord-ouest du Pacifique et permettra de partager les dernières avancées en matière de découverte d’anticorps », observe Steve Lavezoli, vice-président des produits biologiques chez Curia. Et de poursuivre : « Nous sommes également impatients d’échanger sur nos meilleurs flux de travail, de haute qualité et accélérés pour la découverte, le développement et la fabrication clinique d’anticorps en vue d’une première administration chez l’être humain. Les anticorps découverts et/ou conçus à l’aide de la plateforme technologique de Curia sont utilisés en clinique et nous avons mené avec succès plus de 230 campagnes de découverte d’anticorps au bénéfice de la communauté biotechnologique. »

La rapidité, l’expertise scientifique et l’efficacité permettent de surmonter les forts taux de rotation de la découverte précoce d’anticorps et d’assurer la mise en marché de nouveaux produits thérapeutiques. Le symposium mettra en lumière la plateforme technologique et les services intégrés de Curia, en exerçant un focus sur le développement de modèles murins améliorés pour la génération d’anticorps et le criblage de cellules B uniques à haut débit. La combinaison du séquençage de nouvelle génération (SNG) et de la production recombinante rapide de quantités d’anticorps monoclonaux (AcM) purifiés (de milligramme en gramme) accélère considérablement l’identification des approches de développement de produits candidats.

Depuis 2017, Carterra commercialise son puissant biocapteur à haut débit LSA®, conçu pour l’analyse et la caractérisation des anticorps à l’aide de la résonance plasmonique de surface (ou SPR pour Surface Plasmon Resonance). Depuis le lancement de sa plateforme LSAXT l’année dernière, Carterra propose des produits en mesure d’effectuer l’analyse de petites molécules et permettre la découverte d’anticorps. La plateforme LSA a fait l’objet de plusieurs articles évalués par des pairs dans Science, Nature et Cell, détaillant le parcours de plusieurs produits thérapeutiques faisant leur entrée dans les essais cliniques. Lors du symposium, plusieurs scientifiques renommés du secteur biopharmaceutique partageront les éclairages propres à leurs domaines spécifiques de découverte de médicaments et mettront en évidence l’effet novateur de l’intégration de la technologie HT-SPR, de l’intelligence artificielle et de l’apprentissage automatique et d’autres nouvelles technologies.

« Nous sommes enchantés de nous associer à Curia pour organiser ce symposium. Les symposiums de Carterra sont des événements scientifiques que nous organisons chaque année aux États-Unis et en Europe », précise Chris M. Silva, vice-président du marketing et des produits chez Carterra, avant d’ajouter : « Ils nous permettent de partager les dernières avancées technologiques et les données significatives générées par les flux de travail des scientifiques utilisant les plateformes sans étiquette de Carterra. Nous rendre dans le nord-ouest du Pacifique nous permettra d’induire une meilleure compréhension de la technologie applicable aux domaines pharmaceutique et biotechnologique dans cette région. »

Cliquez ici pour vous inscrire à l’événement. L’inscription est obligatoire car le nombre de places est limité.

À propos de Curia :
Curia est une organisation de développement et de fabrication sous contrat (ou CDMO pour Contract Development and Manufacturing Organization) avec plus de 30 ans d’expérience à son actif, qui exploite un réseau intégré de 27 sites à travers le monde et emploie plus de 3 500 collaborateurs travaillant en partenariat avec des clients biopharmaceutiques pour commercialiser des traitements ayant un véritable impact sur la vie des personnes. Nos offres de produits biologiques et de petites molécules vont de la découverte à la commercialisation, et intègrent des capacités réglementaires et analytiques intégrées. Nos scientifiques, nos experts en processus et nos installations de pointe apportent une expérience de premier ordre dans la fabrication de substances et de produits pharmaceutiques. De la curiosité au traitement, nous réalisons toutes les étapes pour améliorer la vie des patients. Consultez notre site à l’adresse suivante : www.curiaglobal.com.

À propos de Carterra, Inc. :
Carterra, Inc. est une société privée. Sa technologie HT-SPR délivre aux clients du secteur de la découverte de médicaments à petites et grandes molécules un débit de criblage et de caractérisation et des fonctionnalités qui s’adaptent aux applications de niveau omique, ramenant ainsi des mois de travail à quelques jours à peine. Nos solutions ont permis la mise au point de nombreux traitements et de recherches révolutionnaires. Elles ont appuyé les chercheurs universitaires et translationnels ainsi que les sociétés biopharmaceutiques spécialisés dans les domaines de l’oncologie, de l’immunologie, des neurosciences, entre autres. Carterra est domiciliée à Salt Lake City, dans l’Utah, et exploite des centres d’expérience client situés à San Francisco, Salt Lake City et Boston, ainsi qu’à Manchester, en Angleterre, et à Munich, en Allemagne. Les produits Carterra sont disponibles en Asie-Pacifique et en Océanie par l’intermédiaire de notre distributeur exclusif, Revvity. Pour en savoir plus, consultez le site www.carterra-bio.com ou retrouvez-nous sur LinkedIn ou X (Twitter).

Coordonnées Curia :
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Interlocutrice auprès des médias :
Cheri Salazar
(408) 594-9400
csalazar@carterra-bio.com

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/020a0a28-86f0-4f6c-96f2-0eaa01c82784

GlobeNewswire Distribution ID 9115418

Ghana shows robust commitment to digitisation, achieving substantial progress


Mr Charles Abani, the United Nations Resident Coordinator, said Ghana has shown robust commitment to digitisation, achieving substantial progress in key economic sectors.

He said the widespread adoption of digital technologies and the internet had transformed global communication and information access, including areas like social services and governance, as seen in Ghana.

He said this shift was particularly evident during the COVID-19 pandemic, which underscored the internet’s return role in education and daily life, demonstrating the deep integration of digital innovation.

Mr Abani, who was represented by Madam Fatou Diallo Ndiaye, Chief of Missions, Ghana, said this at the launch and dissemination of the assessment of Ghana’s Internet Universality Indicators (IUI) Report in Accra.

The objective of the IUI is to develop a clear and substantive understanding of the national internet environment and of internet policies that contribute to sustainable development and policies, and in addition, formulate p
olicy recommendations that can help improve internet development in the country.

Mr Abani said however, that despite the growing influence of Information Communication and Technology (ICT), a digital divide remained between rural and urban areas even by insufficient infrastructure, social and cultural barriers and disparities related to gender and disability.

He said additionally, the expansion of digital platforms introduced new challenges including issues with privacy, freedom of expression, cybersecurity, and the spread of misinformation and disinformation.

The UN Resident Coordinator said the establishment of the Ministry of Communication and Digitalisation underscored this commitment and made predictions to advance its digital agenda.

He said the strategic role signalled a clear priority invitation of digital transformation as the cornerstone for national development.

Mrs Eva Andoh-Poku, the Acting Administrator of the Ghana Investment Fund for Electronic Communications (GIFEC), said in July 2020, t
he IUI was launched in Ghana through the first meeting of the National Multistakeholder Advisory Board.

She said the completion of the assessment placed Ghana among the very few countries that had taken the lead and completed the task, with about 34 countries progressing steadily toward completion.

‘It is noteworthy to highlight that Benin, Kenya, and Ghana are currently the countries within the African Continent that have completed these assessments, which is very commendable,’ she added.

Mrs Andoh-Poku said since GIFEC was declared as the institutional host of the Information for All Programme, the committee through GIFEC had implemented a campaign for efficient tools for youth to conquer violent extremism which aimed at combating hate speech.

She added that they also campaigned to encourage female participation in the digitalisation process, introducing the ICT Skills for Entrepreneurial and Women Empowerment Programme, to equip women entrepreneurs with ICT skills, thereby enhancing their economic welf
are.

Mr Apollonius Akoto Osei Asare, Chief Programme Officer, Ghana Commission for UNESCO, said the findings of this research were more than just observations since they would serve as the foundation for a policy brief that would inform and guide toward an equitable digital transformation.

He said we must adopt strategies that would not only bridge the digital divide but also propel Ghana towards a future where information and communication technology was a driving force for development and empowerment.

‘As we celebrate this achievement, let us also reaffirm our dedication to ensuring that every Ghanaian has the tools and opportunities to thrive in the digital age,’ the Chief Programme Officer added.

Source: Ghana News Agency

Separatists ambush six government forces in Eyomujock

Separatist Fighters in Eyomujock subdivision in Manyu, South West region, ambushed and killed six government forces including a Brigade commander.

CNA sources hinted that someone cornered Gendarmes that Separatists were on their way to block the Eyomujock-Mamfe road. The brigade commander placed two elements in a truck that pretended to transport goods through the area while he was following them behind with four men.

Separatists ambushed the truck, killed one occupant but one escaped.

They also attacked the vehicle that was trailing the truck, killing the Brigade Commander and four men.They later set the bodies on fire, a security source said.

Source: Cameroon News Agency

Farmers, stakeholders sensitised on PFJ2.0 programme at Dambai


The Department of Agriculture has engaged some stakeholders in the Krachi East Municipality of the Oti Region, on the second phase of the Planting for Food and Jobs programme.

The sensitization, which took place at Pentecost Chapel, exposed the stakeholders to the PFJ2.0 registration process and encouraged them to in turn educate their communities.

Mr Emmanuel Minah, the Municipal Director of Agriculture, indicated that the PFJ2.0 had come to build on the successes of the first phase of the programme.

He stated 11 commodities the government intended to provide to farmers, which include tomatoes, onions, pepper, soya beans, rice, millet seeds, cassava, sorghum and maize.

In addition, he said the government would supply fertilizers such as NPK and urea to farmers.

He emphasized that there was the need to educate the stakeholders on the PFJ2.0 programme to enable them to appreciate the potential impact of programme on farmers and its implementation modalities.

In a presentation, Mr Minah noted that the re
gistration of farmers for the PFJ2.0 is done through a digital platform called the Ghana Agriculture and Agric-business platform.

He encouraged the youth in the Municipality to take advantage of the programme to help contribute to the goal of achieving food and nutrition security.

Heads of Departments and Agencies, representatives of farmers’ Associations and groups among others participated in the event.

Source: Ghana News Agency

Bambili students decry landlord exploitation amidst deteriorating living condition

By Charity Nginyu

Students residing in J andD Residence, situated on Bambili Tangang Street, Bamenda in the North West Region of Cameroon have shared their harrowing experiences of exploitation and neglect by their landlord.

Recounting their ordeal to CNA, one student described the deteriorating living conditions, highlighting the daily struggles tenants face.

‘When we got to our Hostel, an apartment that doesn’t have constant water supply,’ lamented the student, shedding light on the dire lack of basic amenities. He says the absence of essential utilities has plunged residents into hardship, making their daily lives immensely challenging.

Moreover, the student revealed, ‘It’s in a very unsecured zone where Amba boys harass us daily.’

The student went on to detail the financial burdens imposed by the landlord, stating, ‘We used to pay 80k per month for an apartment that’s 960k for 12 months.’ However, the situation has recently taken a turn for the worse as the landlord suddenly increased the rent to 10
0k per month, leaving tenants struggling with escalating costs.

Adding to the distress, the student recounted, ‘All her tenants paid their rent in November but she just came with a communique and canceled everything.’

The arbitrary decision to nullify existing rental agreements has plunged tenants into uncertainty and instability, worsening their already precarious situation.

Unveiling the underlying motives behind the landlord’s actions, the student alleged, ‘The landlady took a loan from the bank to build the Hostel and she’s putting pressure on the poor students to pay the loan and start making profits.’

The student further expressed outrage at the exorbitant rental rates imposed by the landlord, emphasizing that, ‘She even increased the studios which are very very small to 750k per month.’

This said exploitation, coupled with the deplorable living conditions, has sparked widespread condemnation among residents.

The students are calling for urgent intervention to address the injustices they face.

Th
is instance serves as a vivid illustration of the prevalent struggles endured by students, not confined to Bamenda alone but extending to educational hubs like Buea in the South West region.

Source: Cameroon News Agency

GJA lifts media blackout on Mr Farouk Aliu Mahama


The Ghana Journalist Association (GJA) has lifted the media blackout placed on Mr Farouk Aliu Mahama, MP for Yendi.

The Association went through an interim restriction on its media reportage for over three months.

This came after he assaulted Mohammed Aminu Alabira, a Northern Regional Citi News reporter on January 27, 2024.

Speaking at a press conference in Accra, Mr Albert Dwumfour, President of the GJA, said the decision to lift the media blackout on Mr Mahama was influenced by the MP’s illustration of deep regret and his vow to work with journalists to safeguard their safety and security in the country.

‘Mr Mahama apologised for the assault on the Citi FM reporter and committed to working to restore cordial relations with the media in the Northern region and the country as a whole.’

The GJA President said, Mr Mahama also noted that he had also withdrawn the suit against GJA and its partners as well as Citi TV and Citi FM and was ready to meet the management of the media house and the victim, for an
amicable settlement.

Mr Dwumfour added that the MP for Yendi sent a formal letter of apology to the management of Citi FM and Citi TV.

He said the MP also wrote to the GJA to settle the matter between himself, Citi FM, TV, and the GJA.

‘After meeting to discuss the reconciliation gesture by the MP, the pleas by the minister of information designate, together with the positive feedback from the management of Citi TV, the GJA and its partners have decided to end the media boycott placed on the MP.

‘We therefore respectfully, request all media organisations to take note and act according with effect from today, May 9, 2024,’ he added.

Mr Dwumfour added they had previously lifted the media blackout on Mrs Hawa Koomsom, MP for Awutu Senya East Constituency, saying the media blackout on Mrs Koomson was lifted some months earlier, adding that the GJA and its partners would ensure that justice was served.

‘The MP met officials of the GJA and its partners to express regret over the attack of the journalist while
pledging to help identify and arrest the perpetrators. It was based on this pledge which was backed by the minister-designate for information that the blackout was lifted, he added.

He said Mrs Koomson fulfilled her promise of aiding the police in their investigations by identifying two suspects.

Mr Dwumfour, therefore assured that the case was still under investigation by the police to ensure the prosecution of the identified perpetrators.

According to him the implementation of the media blackout had proven to be an effective deterrent adding that ‘after recording the attacks and blacklisting people who attack journalists, it has resulted in the reduction of attacks and has also raised awareness.’

‘This is good for us. It means that the measures and decisions we have taken are biting and everyone is cautious and being careful about the media.’

Source: Ghana News Agency